Dive into the innovative research Altoida presented at global conferences in 2024. Our posters showcase advancements in Alzheimer's disease detection, diagnosis, and care, with a focus on digital biomarkers and machine learning. Below, you can download each paper to gain deeper insights into our findings.
Presented at the 2024 CNS Summit by Marc Jones
This poster discusses our multi-country study evaluating the diagnostic accuracy of the Altoida NeuroMarker Platform, a machine-learning-based cognitive assessment tool. The study highlights the platform's effectiveness in detecting Mild Cognitive Impairment (MCI) and Alzheimer's disease using augmented reality tasks. The research also explores the concordance between Altoida's platform and clinical evaluations, as well as the diagnostic performance in diverse populations across 13 countries.
Presented at ADPD 2024 by M. Florencia Iulita, Ph.D.
This research focuses on the predictivity of Altoida's Digital NeuroSignature (DNS) for identifying cognitive impairment and amyloid positivity in individuals with subjective cognitive complaints and MCI. The study demonstrates the platform’s high concordance with clinical evaluations and amyloid status, supporting its potential as a complementary diagnostic tool for early Alzheimer's detection.
Presented at CTAD 2024 by M. Florencia Iulita, Ph.D.
In this study, we explore the alignment between Altoida’s digital cognitive assessment platform and traditional neuropsychological assessments. The research evaluates how the Altoida platform identifies cognitive impairment associated with amyloid deposition and supports the use of digital biomarkers in early Alzheimer's diagnosis. The findings underscore the potential of integrating Altoida’s technology into routine clinical practice.
Each study reflects our commitment to advancing Alzheimer's research through our NeuroMarker Platform to help enable an early diagnosis. Our platform is designed to leverage digital biomarkers and machine learning to provide accurate, early detection of cognitive impairment.
Learn more about the Altoida NeuroMarker Platform
